Possibilities of immunomodulation in atopic dermatitis: a preliminary trial with broncho-vaxom
Czerniawska-Mysik, G.; Adamek-Guzik, T.; Prochowska-Mitka, K.
Pneumonologia i Alergologia Polska 60(Suppl 2): 113-116
1992
ISSN/ISBN: 0867-7077 PMID: 1305485 Document Number: 4479
Atopic dermatitis is a chronic, hereditarily, mainly pruritic form of eczema, often associated with other atopic diseases, namely asthma and allergic rhinitis. Most of the sufferers react to common inhaled and food allergens by increased formation of immunoglobulin E antibodies. Associated phenomena that have been reported include: an antigenspecific and also a non-specific deficiency in cell-mediated immunity; weak delayed skin responsiveness to certain microbial antigens; decreased blast transformation of lymphocytes cultured with phytohaemagglutinin; and decreased numbers of T lymphocytes. Brocho-Vaxom, an orally administered immunomodulating preparation, is a lyophilised bacterial extract prepared from organisms most frequently being the cause of infections of the respiratory tract. It stimulates lymphocytes and their proliferative responses to certain mitogens, and restores the functions of T lymphocytes in linmunodeficient patients. By inducing the production of antibodies, especially of secretory antibodies, Broncho-Vaxom shares certain properties of vaccines and of adjuvants by modulating cell-mediated immunity, as reflected by its activation of macrophages and other cells.
Document emailed within 1 workday
